Fate Therapeutics Inc FATE:NASDAQ

Last Price$14.54NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/16/19

Today's Change-0.21(1.42%)
Bid (Size)$2.44 (10)
Ask (Size)$14.53 (6)
Day Low / High$14.49 - 15.01
Volume473.5 K
  • Latest Stories
  • Commentary and Analysis
Insider Trends: Insider Sale Eases Back 90-Day Buy Trend at Fate Therapeutics
4:09PM ET 10/16/2019 MT Newswires

J Scott Wolchko, Director and President & CEO, on Oct 15, 2019, sold 21,017 shares in Fate Therapeutics (FATE) for $303,458. Subsequent to the Form 4...

Insider Trends: Fate Therapeutics Sees 90 Days of Insider Buying Trend Reducing with Share Disposition
4:07PM ET 10/16/2019 MT Newswires

Cindy Tahl, General Counsel & Secretary, sold 10,200 shares in Fate Therapeutics (FATE) for $145,292 on Oct 15, 2019. Tahl, following the transactions...

Insider Trends: Fate Therapeutics Insider Disposition Interrupting 90-Day Buy Trend
4:06PM ET 10/16/2019 MT Newswires

Daniel D Shoemaker, Chief Scientific Officer, sold 11,800 shares of Fate Therapeutics (FATE) on Oct 15, 2019, for $168,593. Shoemaker, subsequent to the...

Analyst Actions: Stifel Nicolaus Initiates Coverage on Fate Therapeutics With Buy Rating, $27 Price Target
7:19AM ET 10/01/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $25. Price: 15.53, Change: +0.06, Percent Change: +0.39...

Significant Insider buy of Fate Therapeutics (FATE) Shares Reverses Selling Trend of Last Quarter
10:17PM ET 9/18/2019 MT Newswires

One insider -- Redmile Group Llc, 10% Owner and Director -- today, acquired 857,143 shares of Fate Therapeutics having a market value of approximately...

Fate Therapeutics Closes Stock Offering; Underwriters Boost Gross Proceeds Over $173 Million
4:12PM ET 9/18/2019 MT Newswires

Fate Therapeutics (FATE) slipped 1% in extended trade after the biopharmaceuticals company late Wednesday said underwriters participating in its recent...

Significant Insider buy of Fate Therapeutics (FATE) Shares Reverses Selling Trend of Last Quarter
9:53AM ET 9/18/2019 MT Newswires

One Fate Therapeutics insider -- Redmile Group Llc, 10% Owner and Director -- today, acquired 857,143 shares having a market value of approximately...

Insider Trends: Insider Buying Prolonged with Purchase of Fate Therapeutics Stock
4:24PM ET 9/17/2019 MT Newswires

Redmile Group Llc, 10% Owner and Director, reported a purchase of 857,143 shares of Fate Therapeutics (FATE) on Sep 16, 2019, for $15,000,003. Redmile...

Analyst Actions: Piper Jaffray Cuts Fate Therapeutics PT to $28 From $30, Maintains Overweight Rating
9:31AM ET 9/16/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $25. Price: 17.93, Change: +0.48, Percent Change: +2.75...

Fate Therapeutics Prices Public Offering of Shares at Discount; Shares Slump
3:00PM ET 9/12/2019 MT Newswires

Fate Therapeutics (FATE) shares fell Thursday after the clinical-stage biopharmaceutical company said it has priced an underwritten public offering of its...